Table 2. Complement analytes in the Washington University School of Medicine (WUSM) COVID-19 cohort.

	Non-ICU (N=62)	ICU (N=72)	p
sC5b-9 (ng/mL)	559.5 (343.3 – 813.0)	715.4 (448.5 – 1,084.0)	0.0335
C5a (pg/mL)*	635.0 (471.9 – 892.6)	918.4 (666.7 – 1,081)	0.034
iC3b: C3 ratio*	0.56 (0.51 – 0.65)	0.70 (0.57 – 1.39)	0.002
Factor B, ng/mL*	21,606 (17,834 – 26,853)	25,840 (20,544 – 32,832)	0.033
AP hemolytic activity, %**	85.0 (76.0 – 102.5)	81.0 (74.5 – 90.0)	0.2519
Ba, ng/mL*	1,191 (901.3 – 1,981)	3,112 (2,022-6,612)	<0.0001
Factor D, ng/mL*	4,640.3 (3,659 – 9,887.3)	6,622.5 (4,308 – 10,854.1)	0.166

*C5a, iC3b: C3 ratio, Factor B, Ba and Factor D were measured in 48 patients, among whom 26 needed an intensive care unit (ICU) admission and 22 did not. **Alternative pathway (AP) hemolytic activity was performed in 38 patients (21 ICU, 17 non-ICU) based on the availability of samples. Statistical tests for comparison were done using the Mann-Whitney U test. Values are represented as median (interquartile range).